The decisions you may face, the aids that walk through them, the warnings on record, the first sixty days and the questions to ask.
One section per setting: the options named, what each is for, the trials behind them, the recorded trade-offs and the questions to ask.
Persistent headache with extreme tiredness, nausea, dizziness on standing or low blood pressure. Vomiting, severe weakness or collapse is adrenal crisis.
Fainting, near-fainting, or an irregular or racing heartbeat; several kinase inhibitors prolong the QT interval and the labels require ECG and electrolyte monitoring.
Blisters, peeling, or sores in the mouth or eyes with a rash. Enfortumab vedotin carries a boxed warning for Stevens-Johnson syndrome and toxic epidermal necrolysis, mostly in the first cycle.
Temperature of 38 C or higher, or feeling shivery and unwell even without a fever. Antibody-drug conjugates suppress the bone marrow, and several carry a boxed warning for severe neutropenia.
Tingling, numbness or weakness that affects walking or using the hands; peripheral neuropathy is common with the vedotin (MMAE) payload and doses are reduced or stopped at grade 2 to 3.
Hyperglycaemia: hold if glucose above 13.9 mmol/L (250 mg/dL).
See all on the product pages:AK146D1AtezolizumabAvelumabDisitamab vedotinDurvalumabEnfortumab vedotinErdafitinibIzalontamab brengitecanNivolumabPembrolizumabSacituzumab tirumotecan·Printable cards in the navigator
Newly diagnosed? Read the first 60 days with Bladder & urothelial cancer, then print the one-page appointment sheet with room for the answers.
Print this page for your appointment (your browser's print command). These prompts are for discussion; your clinical team knows your case.